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ABSTRACT
Background Ibrutinib is a tyrosine kinase inhibitor
most commonly associated with atrial fibrillation.
However, additional cardiotoxicities have been
identified, including accelerated hypertension. The
incidence and risk factors of new or worsening
hypertension following ibrutinib treatment are not as
well known.
Methods We conducted a retrospective study of
144 patients diagnosed with B cell malignancies
treated with ibrutinib (n=93) versus conventional
chemoimmunotherapy (n=51) and evaluated their
effects on blood pressure at 1, 2, 3 and 6 months
after treatment initiation. Descriptive statistics were
used to compare baseline characteristics for each
treatment group. Fisher’s exact test was used to
identify covariates significantly associated with the
development of hypertension. Repeated measures
analyses were conducted to analyse longitudinal blood
pressure changes.
Results Both treatments had similar prevalence
of baseline hypertension at 63.4% and 66.7%,
respectively. There were no differences between
treatments by age, sex and baseline cardiac
comorbidities. Both systolic and diastolic blood
pressure significantly increased over time with
ibrutinib compared with baseline, whereas
conventional chemoimmunotherapy was not
associated with significant changes in blood
pressure. Baseline hypertensive status did not affect
the degree of blood pressure change over time.
A significant increase in systolic blood pressure
(defined as more than 10 mm Hg) was noted for
ibrutinib (36.6%) compared with conventional
chemoimmunotherapy (7.9%) at 1 month after
treatment initiation. Despite being hypertensive
at follow-up, 61.2% of patients who were treated
with ibrutinib did not receive adequate blood
pressure management (increase or addition of blood
pressure medications). Within the ibrutinib group,
of patients who developed more than 20 mm Hg
increase in systolic blood pressure, only 52.9% had
hypertension management changes.
Conclusions Ibrutinib is associated with the
development of hypertension and worsening of blood
pressure. Cardiologists and oncologists must be aware
of this cardiotoxicity to allow timely management of
blood pressure elevations.

INTRODUCTION
Ibrutinib is a Bruton’s tyrosine kinase inhibitor (TKI) that is used to treat chronic lymphoid
leukaemia, Waldenstrom’s macroglobulinaemia,
as well as other conditions such as mantle cell
lymphoma and marginal zone lymphoma.1–6 Its
mechanism of action is through blocking B cell
signalling and targeting other downstream transcription factors, resulting in reduced expression
of CD20 and ultimately promoting apoptosis and
reducing cell proliferation.4 7–9 However, ibrutinib
has known cardiotoxicities, including atrial and
ventricular arrhythmias as well as hypertension.10–15
Unlike various other TKIs, the mechanism of ibrutinib blood pressure (BP) elevations is not due to
inhibition of the vascular endothelial growth factor
(VEGF) pathway and is yet to be fully elucidated.16
While initial reports suggested the incidence of
ibrutinib-related hypertension was relatively modest
(5%–18%),1 2 6 17 more recent studies suggest a
much higher burden.10 16 In fact, a recent study by
Dickerson et al16 reported new or worsening hypertension in 78.3% of patients treated with ibrutinib.
Our study compared the incidence of new or worsening hypertension for ibrutinib therapy versus
conventional chemoimmunotherapy regimens for B
cell malignancies and to assess the management of
hypertension associated with these therapies.

METHODS
Study population

The patient population was derived from our
previously described cohort of 137 patients diagnosed with B cell malignancies treated with ibrutinib therapy and 107 patients with conventional
chemoimmunotherapy
(lenalidomide/rituximab,
fludarabine/cyclophosphamide/rituximab or bendamustine/rituximab) between 1 January 2010 and 31
December 2017.15 In the original cohort, patients in
the treatment groups (ibrutinib therapy vs conventional chemoimmunotherapy) were frequency-
matched on age and sex to ensure no significant
differences and to eliminate potential confounding
from these covariates. The subcohort was not
frequency-matched by age and sex.
Inclusion criteria were patients ≥18 years with
documented vital signs at baseline, at 1 month and
at least one additional assessment at 2, 3 and/or 6
months after initiation of cancer therapy. Patients
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Data collection
The electronic medical records were evaluated to abstract baseline characteristics including demographics, cardiovascular
comorbidities, cardiovascular medications and hospitalisations.
BP was recorded at baseline and at 1, 2, 3 and/or 6 months time
points after cancer treatment initiation or until treatment was
stopped. All BP measurements were obtained from outpatient
clinic visits at Moffitt Cancer Center. Hypertension was defined
as BP ≥130/80 mm Hg or use of antihypertensive medications
based on 2017 American Heart Association/American College
of Cardiology hypertension criteria. Over the course of cancer
treatment, initiation or discontinuation of antihypertensive
medications or dose adjustments were recorded. The data set
was reviewed for accuracy by a second, independent investigator.

Data analysis
Data are presented as count and percentage for categorical
data and mean with SD for continuous data. Fisher’s exact test
was used to test for differences between the two patient groups
for categorical covariates and Student’s t-test was used to test
for differences for continuous covariates. Repeated measures
analysis using a fixed effects general linear model with baseline BP included as a covariate and a variance components
covariance was conducted to assess changes in SBP and DBP
over three time points with assessment of the main interaction
effect. We have performed post-hoc Bonferroni test. In addition to the baseline and 1-month follow-up BP measurements,
we also generated a third time point summary measurement
which combined BP measures at 2, 3 or 6 months using the
earliest available time points. The third time point summary
measurement was generated because BP measurements were
not uniformly assessed after the 1-month measurements. As
such, this ensured at least two sets of vital signs were evaluated after the initiation of cancer therapy as described in the
Study population section. SPSS V.24.0 was used for statistical
analysis. A p value of less than 0.05 was considered statistically
significant.

Patient and public involvement
Patients and the public were not involved in the development of
question, design, recruitment, conduct or outcome measures of
the current research study.
2

RESULTS
From the original cohort, 93 patients treated with ibrutinib and
51 patients treated with conventional chemoimmunotherapy met
the inclusion criteria for the current analysis. Baseline patient
demographics are presented in table 1. The two groups were
well matched without significant differences in baseline comorbidities or medications. Compared with conventional chemoimmunotherapy group, more patients treated with ibrutinib
demonstrated a significant increase in BP over time. Between
baseline and 1 month, 18.3% of patients treated with ibrutinib
had an increase in their SBP of between 10 mm Hg and 19 mm
Hg, and an additional 18.3% experienced an increase in SBP of
≥20 mm Hg. In contrast, only 7.9% of patients in the conventional chemoimmunotherapy group experienced an SBP increase
of more than 10 mm Hg from baseline.
The mean baseline SBP and DBP were significantly higher in
the conventional chemoimmunotherapy group (129/77 mm Hg)
compared with the ibrutinib-
treated group (122/72 mm Hg).
However, there was no significant difference in the number of
patients meeting the study definition of hypertension (ibrutinib
63.4%, conventional chemoimmunotherapy 66.7%, p=0.720).
The lower baseline BP in the ibrutinib group was not driven by
excess antihypertensive therapy; in fact, baseline BP was actually
higher in patients taking antihypertensive medications at baseline (125/74 mm Hg vs 117/70 mm Hg, p=0.008 and p=0.055
for SBP and DBP, respectively). Of note, when the criteria for
hypertension were used based on prior guidelines (BP ≥140/90
or use of antihypertensive medications), the number of patients
with hypertension at baseline was lower (ibrutinib 51.6%,
conventional chemoimmunotherapy 56.9%, p=0.547).
In the ibrutinib group, 59 (63.4%) patients had baseline
hypertension compared with 34 (66.7%) patients in the conventional chemoimmunotherapy group. The number of patients
who had hypertension at 1 month increased to 67 (72%) patients
in the ibrutinib group, while there was a decrease to 28 (54.9%)
patients in the conventional chemoimmunotherapy group. From
the 2–6 months summary data, there was no difference in the
incidence of hypertension between the ibrutinib group (71%,
n=66) and the conventional chemoimmunotherapy group
(68.6%, n=35, p=0.849).
Repeated measures analyses demonstrated statistically
significant difference in mean SBP and DBP (both p<0.010)
over the three recorded time points within each treatment group (figure 1). Using post-
hoc Bonferroni analysis to compare baseline, 1 month and 2, 3 or 6 months BP
values, ibrutinib patients demonstrated a statistically significant change (p<0.001) for each comparison (baseline BP:
122/72 mm Hg; 1 month BP: 130/74 mm Hg; 2, 3 or 6 months
BP: 133/76 mm Hg). Using the same method for the conventional chemoimmunotherapy group, there was a significant
decrease in BP at 1 month (baseline BP: 129/77 mm Hg;
1 month BP: 123/73 mm Hg; p=0.006). However, there was
no significant difference from baseline and at 2, 3 or 6 months
time points (BP 127/75 mm Hg, p=0.923). In addition, there
were no statistically significant changes in SBP between
baseline/1 month (∆A) and baseline/2–6 months (∆B) (∆A
+8.4±16.4 mm Hg and ∆B 11.5±16.4 mm Hg, p=0.239)
in the ibrutinib group (figure 1). In comparison, changes in
SBP between baseline/1 month (∆A) and baseline/2–6 months
(∆B) were statistically significant (∆A −6.2±12.6 mm Hg
and ∆B 0.0±15.6 mm Hg, p=0.003) in the conventional
chemoimmunotherapy group. The BP change patterns
were different between the ibrutinib and conventional
Lee DH, et al. Heart 2021;0:1–6. doi:10.1136/heartjnl-2021-319110
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(ibrutinib group n=137, conventional chemoimmunotherapy
group n=107) from the original publication15 were excluded
from this analysis if they did not have the requisite vital sign
measurements recorded in the electronic medical record.
The final analytical sample size was 144 patients (93 patients
treated with ibrutinib therapy and 51 treated with conventional
chemoimmunotherapy).
Due to the reduced sample size from our original publication,
we performed post-hoc power calculations18 to detect a significant difference in mean vital sign measurements between the two
treatment groups. The post-hoc power calculations were based
on the main effects of an overall mean change and not based
on repeated measures. Based on an alpha of 0.05, and assuming
a mean systolic blood pressure (SBP) of 130 mm Hg, diastolic
blood pressure (DBP) of 90 mm Hg, and heart rate of 80 beats
per minute and SD of 10 for all measurements, we have at least
82% power to detect a statistically significant mean difference of
5 mm Hg or beats per minute for each measure.

Cardiac risk factors and prevention
Patient demographics by chemotherapy regimens
Patients treated with ibrutinib (n=93)

Patients treated with conventional
chemoimmunotherapy (n=51)

P value*

Age at onset of therapy, mean±SD

66.9±10.7

64.2±9.1

0.143

Sex, male, n (%)

64 (68.8)

34 (66.7)

0.853

BMI, mean±SD

27.6±5.3

28.4±5.8

0.374

Smoking history, n (%)

52 (55.9)

28 (54.9)

1.000

SBP at baseline

121±15

129±17

0.008

DBP at baseline

72±10

77±8

0.001

Heart rate at baseline

80±15

77±12

0.143

 Hypertension†

59 (63.4)

34 (66.7)

0.720

 Diabetes mellitus

20 (21.5)

11 (21.6)

1.000

 Hyperlipidaemia

46 (49.5)

23 (45.1)

0.728

 Coronary artery disease

16 (17.2)

12 (23.5)

0.384

 Atrial fibrillation

10 (10.8)

8 (15.7)

0.435

 Cardiomyopathy

6 (6.5)

3 (5.9)

1.000

 Stroke

2 (2.2)

3 (5.9)

0.346

 ACEi

12 (12.9)

6 (11.8)

1.000

 ARB

11 (11.8)

2 (3.9)

0.138

 Beta blocker

22 (23.7)

10 (19.6)

0.677

 CCB

14 (15.1)

6 (11.8)

0.626

 Thiazide

10 (10.8)

5 (9.8)

1.000

 Loop diuretics

5 (5.4)

1 (2.0)

0.423

 Nitrates

0 (0)

0 (0)

Baseline comorbidities, n (%)

Baseline cardiovascular medications, n (%)

 Statin

28 (30.1)

20 (39.2)

 Aspirin

23 (24.7)

17 (33.3)

0.331
<0.001

Malignancy type, n (%)
 Chronic lymphocytic leukaemia

70 (75.3)

27 (52.9)

 Mantle cell lymphoma

11 (11.8)

24 (47.1)

 Waldenstrom’s macroglobulinaemia

10 (10.8)

0 (0)

2 (2.2)

0 (0)

 Other

0.356

*P values were derived from Fisher’s exact test for categorical variables and Student‘s t-test for continuous variables. All p values are two-sided, and p value in bold is statistically
significant.
†Hypertension was defined by individual chart review through SBP ≥130 or DBP ≥80 or on antihypertensive medications.
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure.

chemoimmunotherapy group (p<0.001 for both SBP and
DBP), with a trend towards an increase primarily in SBP in
the ibrutinib group.
When adjusting for baseline hypertension, these changes were
no longer statistically significant (figure 2). There were no statistically significant differences in BP changes after initiation of
ibrutinib based on baseline hypertension status, with both baseline hypertension and no hypertension groups having increase in
SBP (figure 2A) and DBP (figure 2B) at 1 month after initiation
of ibrutinib.
Overall, patients with baseline hypertension did not
get sufficient treatment for hypertension for both groups
treated with ibrutinib or conventional chemoimmunotherapy. Among patients in the ibrutinib group who developed hypertension, 38.8% had management changes
(increase or addition of antihypertensive medication),
whereas 61.2% did not get management changes. Of the
patients who developed an SBP increase of >20 mm Hg,
only 52.9% had hypertension management changes. The
degree of management changes for hypertension was similar
in the conventional chemoimmunotherapy group (39.3%
with management changes).
Lee DH, et al. Heart 2021;0:1–6. doi:10.1136/heartjnl-2021-319110

DISCUSSION
This study found that the incidence of new or worsening hypertension was greater in patients treated with ibrutinib compared with
patients receiving conventional chemoimmunotherapy, with the
largest increase occurring within the first month of therapy. These
data are consistent with recent studies reporting a significantly
elevated incidence of ibrutinib-related hypertension.16 Longitudinal
analyses demonstrated that ibrutinib use was consistently associated
with increasing BP. Interestingly, the conventional chemoimmunotherapy group demonstrated a decline in BP at the 1-month time
point, which may be attributed to a mild autonomic dysfunction
which commonly occurs in the setting of cytotoxic chemotherapy.19
Also, despite the lower average BP at baseline in the ibrutinib group
compared with the conventional chemoimmunotherapy group, the
ibrutinib group had greater increases in their BP (particularly SBP)
from baseline values and a trend towards increased values over time.
Previous safety analyses of ibrutinib demonstrated a 3% incidence of developing hypertension compared with 1% with conventional chemoimmunotherapy.20 However, subsequent studies have
suggested a much higher incidence of developing new or worsening
hypertension, up to 40% in one observational study.10 21 Most
recently, a retrospective study of 562 patients treated with ibrutinib
3
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over a median follow-up of 30 months reported hypertension in
78.3%, with 71.6% developing new-onset hypertension and 82.4%
worsening of their baseline high BP. The average time to developing
ibrutinib-associated hypertension was 1.8 months (50% cumulative
incidence). Treatment of ibrutinib-induced hypertension reduces the
risk of subsequent major adverse cardiac events (defined as stroke,
myocardial infarction, heart failure and cardiac arrhythmia, in addition to cardiovascular death); however, no specific antihypertensive
class was more efficacious.16 In our study, patients in neither treatment group were adequately initiated on antihypertensive medications when BP elevations were identified. It is essential to raise
awareness on ibrutinib association with hypertension to allow for
expeditious initiation of antihypertensives to avoid the adverse acute
and chronic cardiovascular consequences associated with uncontrolled hypertension, including myocardial infarction, renal dysfunction and stroke.
4

Figure 2 Box plot for changes in blood pressure from baseline to
1 month by treatment and baseline hypertension status. Systolic (A) and
diastolic (B) blood pressure changes from baseline and 1 month were
not different between hypertension (red bar) and normotension (blue
bar) in both ibrutinib and conventional chemoimmunotherapy groups.
Changes in systolic and diastolic blood pressure were significantly
different overall for ibrutinib versus conventional chemoimmunotherapy
(p<0.001) in the ibrutinib group. ∆, change in blood pressure; DBP,
diastolic blood pressure; HTN, hypertension; NS, not statistically
significant; SBP, systolic blood pressure.
The mechanism by which ibrutinib exerts its hypertensive effects
remains unclear, although one proposed mechanism is off-
target
downregulation of the VEGF pathway through Bruton’s tyrosine
kinase inhibition.22 Hypertension is a common on-target cardiotoxicity of VEGF inhibitors, a class of TKIs including sunitinib, axitinib
and pazopanib used to treat various solid and liquid tumours.23
VEGF inhibitor hypertension may be related to decreased nitric
oxide bioavailability, microvascular rarefaction, and/or production of
endogenous vasoactive substances including endothelin-1 and sFlt-1,
leading to increased systemic vascular resistance.16 24 25
We acknowledge some limitations to this study. First, this is a retrospective study from a single centre which may not be generalisable
Lee DH, et al. Heart 2021;0:1–6. doi:10.1136/heartjnl-2021-319110
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Figure 1 Changes in blood pressure over time based on treatment
group. (A) Changes in systolic blood pressure over time based on
treatment regimen. Ibrutinib treatment causes significant increase in
systolic blood pressure over time compared with baseline. (B) Changes
in diastolic blood pressure over time based on treatment regimen. In
a repeated measure post-hoc Bonferroni test, there was statistically
significant increase in blood pressure at 1 month and at 2–6 months
summary data when compared with baseline (p<0.001) in the ibrutinib
group.

Cardiac risk factors and prevention

Key messages
What is already known on this subject?

►► The Bruton’s tyrosine kinase inhibitor ibrutinib is used to treat

various B cell malignancies and is associated with various
cardiotoxicities including arrhythmias.

What might this study add?

►► The present study demonstrates that hypertension is also an

important cardiotoxicity of ibrutinib when compared with
conventional chemoimmunotherapy.
►► A significant increase in blood pressure of more than 10 mm
Hg was seen in 36% of patients on ibrutinib, with the
majority of patients receiving inadequate treatment for their
hypertension.
How might this impact on clinical practice?

►► Both cardiologists and oncologists must be aware of this

cardiotoxicity and aggressively manage blood pressure
elevations in patients on ibrutinib to reduce long-term
adverse cardiovascular outcomes.

Lee DH, et al. Heart 2021;0:1–6. doi:10.1136/heartjnl-2021-319110
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